Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY. Osiyemi O, et al. Among authors: wang r. Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY. van Wyk J, et al. Among authors: wang r. Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243. Clin Infect Dis. 2020. PMID: 31905383 Free PMC article. Clinical Trial.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Matthews J, Wang R, Underwood M, Wynne B, Nascimento MC, Vandermeulen K, Gartland M, Smith KY. van Wyk J, et al. Among authors: wang r. J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):325-330. doi: 10.1097/QAI.0000000000002449. J Acquir Immune Defic Syndr. 2020. PMID: 32675772 Free PMC article. Clinical Trial.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Underwood M, et al. Among authors: wang r. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694877 Free PMC article. Clinical Trial.
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Underwood M, et al. Among authors: wang r. Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0032622. doi: 10.1128/aac.00326-22. Epub 2023 Feb 16. Antimicrob Agents Chemother. 2023. PMID: 36794938 Free PMC article. No abstract available.
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
Wang R, Underwood M, Llibre JM, Bernal Morell E, Brinson C, Sanz Moreno J, Scholten S, Moore R, Saggu P, Oyee J, Moodley R, Wynne B, Kisare M, Jones B, Ait-Khaled M. Wang R, et al. Open Forum Infect Dis. 2023 Dec 9;11(1):ofad626. doi: 10.1093/ofid/ofad626. eCollection 2024 Jan. Open Forum Infect Dis. 2023. PMID: 38213637 Free PMC article.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
De Wit S, Bonnet F, Osiyemi O, Bisshop F, Olalla J, Routy JP, Wyen C, Moodley R, Pappa K, Wang R, Oyee J, Saggu P, Letang E, Wynne B, Jones B, Smith KY, Ait-Khaled M. De Wit S, et al. Among authors: wang r. J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003395. Online ahead of print. J Acquir Immune Defic Syndr. 2024. PMID: 38346427
42,290 results
You have reached the last available page of results. Please see the User Guide for more information.